Apremilast for a psoriasis patient with HIV and hepatitis C

Abstract

A 46-year old male with HIV, hepatitis C, and moderate psoriasis was resistant to starting ultra violet B phototherapy due to scheduling issues. The patient had 8% body surface area (BSA) affected on the dorsal hands, elbows, and legs, did not have associated psoriatic arthritis, and had not tried any systemic therapy in the past. He was initiated on an apremilast starter pack (dosages titrated up from 10 mg to 30 mg over the course of one week) and maintained on 30 mg twice a day after one week.

This article is protected by copyright. All rights reserved.

http://ift.tt/2oNT2OU